Current and Emerging Strategies to Treat Urothelial Carcinoma
Open Access
Abstract
Urothelial cell carcinoma (UCC, bladder cancer, BC) remains a difficult-to-treat malignancy with a rising incidence worldwide. In the U.S., UCC is the sixth most incident neoplasm and ~90% of diagnoses are made in those >55 years of age; it is ~four times more commonly observed in men than women. The most important risk factor for developing BC is tobacco smoking, which accounts for ~50% of cases, followed by occupational exposure to aromatic amines and ionizing radiation. The standard of care for advanced UCC includes platinum-based chemotherapy and programmed cell death (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors, administered as frontline, second-line, or maintenance therapy. UCC remains generally incurable and is associated with intrinsic and acquired drug and immune resistance. UCC is lethal in the metastatic state and characterized by genomic instability, high PD-L1 expression, DNA damage-response mutations, and a high tumor mutational burden. Although immune checkpoint inhibitors (ICIs) achieve long-term durable responses in other cancers, their ability to achieve similar results with metastatic UCC (mUCC) is not as well-defined. Here, we discuss therapies to improve UCC management and how comprehensive tumor profiling can identify actionable biomarkers and eventually fulfill the promise of precision medicine for UCC patients.Keywords
All Related Versions
This publication has 190 references indexed in Scilit:
- Matrix Metalloproteinases and Bladder Cancer: What is New?ISRN Urology, 2012
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Bladder cancer, a review of the environmental risk factorsEnvironmental Health, 2012
- Association Between Smoking and Risk of Bladder Cancer Among Men and WomenJAMA, 2011
- Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysisBMC Cancer, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisGenes & Cancer, 2011
- Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder CancerJournal of Clinical Oncology, 2010
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology: Seminars and Original Investigations, 2010
- Generation of a Concise Gene Panel for Outcome Prediction in Urinary Bladder CancerJournal of Clinical Oncology, 2009